NEWTOWN, Pa.----CollaGenex Pharmaceuticals, Inc. today announced that it has initiated enrollment in a 40 mg cohort in its Phase II double-blinded, placebo-controlled, dose-finding clinical trial to determine the appropriate dose for Phase III testing of incyclinide in the treatment of acne.
From: biz.yahoo.com
CollaGenex Pharmaceuticals Initiates 40 mg Cohort in the Phase II Dose-Finding Study of Incyclinide for the Treatment ...
Posted by Ruslan Abuzant at 6:07 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment